AU2016254685B2 - Combinations of cannabinoids and N-acylethanolamines - Google Patents

Combinations of cannabinoids and N-acylethanolamines Download PDF

Info

Publication number
AU2016254685B2
AU2016254685B2 AU2016254685A AU2016254685A AU2016254685B2 AU 2016254685 B2 AU2016254685 B2 AU 2016254685B2 AU 2016254685 A AU2016254685 A AU 2016254685A AU 2016254685 A AU2016254685 A AU 2016254685A AU 2016254685 B2 AU2016254685 B2 AU 2016254685B2
Authority
AU
Australia
Prior art keywords
cannabinoid
salt
acylethanolamine
pharmaceutical composition
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016254685A
Other languages
English (en)
Other versions
AU2016254685A1 (en
Inventor
Ephraim Brener
Elran HABER
Ascher Shmulewitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurothera Labs Inc
Original Assignee
Neurothera Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurothera Labs Inc filed Critical Neurothera Labs Inc
Publication of AU2016254685A1 publication Critical patent/AU2016254685A1/en
Application granted granted Critical
Publication of AU2016254685B2 publication Critical patent/AU2016254685B2/en
Assigned to SCISPARC LTD reassignment SCISPARC LTD Amend patent request/document other than specification (104) Assignors: Therapix Biosciences Ltd.
Priority to AU2021206784A priority Critical patent/AU2021206784B2/en
Priority to AU2023251426A priority patent/AU2023251426B2/en
Priority to AU2025287414A priority patent/AU2025287414A1/en
Assigned to NEUROTHERA LABS INC. reassignment NEUROTHERA LABS INC. Request for Assignment Assignors: SCISPARC LTD
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
AU2016254685A 2015-04-29 2016-04-19 Combinations of cannabinoids and N-acylethanolamines Active AU2016254685B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2021206784A AU2021206784B2 (en) 2015-04-29 2021-07-19 Combinations of cannabinoids and N-acylethanolamines
AU2023251426A AU2023251426B2 (en) 2015-04-29 2023-10-17 Combinations of cannabinoids and N-acylethanolamines
AU2025287414A AU2025287414A1 (en) 2015-04-29 2025-12-31 Combinations of cannabinoids and N-acylethanolamines

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562154144P 2015-04-29 2015-04-29
US62/154,144 2015-04-29
PCT/IL2016/050414 WO2016174661A1 (en) 2015-04-29 2016-04-19 Combinations of cannabinoids and n-acylethanolamines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021206784A Division AU2021206784B2 (en) 2015-04-29 2021-07-19 Combinations of cannabinoids and N-acylethanolamines

Publications (2)

Publication Number Publication Date
AU2016254685A1 AU2016254685A1 (en) 2017-11-09
AU2016254685B2 true AU2016254685B2 (en) 2021-04-22

Family

ID=57199061

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2016254685A Active AU2016254685B2 (en) 2015-04-29 2016-04-19 Combinations of cannabinoids and N-acylethanolamines
AU2021206784A Active AU2021206784B2 (en) 2015-04-29 2021-07-19 Combinations of cannabinoids and N-acylethanolamines
AU2023251426A Active AU2023251426B2 (en) 2015-04-29 2023-10-17 Combinations of cannabinoids and N-acylethanolamines
AU2025287414A Pending AU2025287414A1 (en) 2015-04-29 2025-12-31 Combinations of cannabinoids and N-acylethanolamines

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2021206784A Active AU2021206784B2 (en) 2015-04-29 2021-07-19 Combinations of cannabinoids and N-acylethanolamines
AU2023251426A Active AU2023251426B2 (en) 2015-04-29 2023-10-17 Combinations of cannabinoids and N-acylethanolamines
AU2025287414A Pending AU2025287414A1 (en) 2015-04-29 2025-12-31 Combinations of cannabinoids and N-acylethanolamines

Country Status (12)

Country Link
US (7) US11234956B2 (https=)
EP (2) EP4193993A3 (https=)
JP (2) JP6938465B2 (https=)
CN (2) CN107530317A (https=)
AU (4) AU2016254685B2 (https=)
CA (1) CA2984088C (https=)
DK (1) DK3288553T3 (https=)
ES (1) ES2935605T3 (https=)
IL (2) IL291864A (https=)
MA (1) MA41997A (https=)
PL (1) PL3288553T3 (https=)
WO (1) WO2016174661A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4193993A3 (en) * 2015-04-29 2023-07-19 Scisparc Ltd. Combinations of cannabinoids and n-acylethanolamines
US20210052478A1 (en) * 2018-01-05 2021-02-25 Altus Labs, Llc Personal care compositions
US20220000833A1 (en) * 2018-01-29 2022-01-06 Therapix Biosciences Ltd. Compositions and methods for treating obstructive sleep apnea
EP3773512A4 (en) * 2018-04-03 2021-12-29 Pure Green, LLC Tablet or composition having n-acyl ethanolamine and cannabinoid
WO2020160452A1 (en) * 2019-02-01 2020-08-06 Tess Ventures, Inc. Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies
CA3136124C (en) * 2019-04-15 2024-04-09 Metagenics, Inc. Novel hemp and pea formulation and its use
AU2020263152A1 (en) * 2019-04-23 2021-10-21 SciISparc Ltd. Compositions and methods for potentiating derivatives of 4-Aminophenols
WO2020227440A1 (en) * 2019-05-07 2020-11-12 Ojai Energetics Pbc Methods for optimized cannabinoid dosage determination
EP3972573A4 (en) 2019-05-23 2023-07-12 India Globalization Capital, Inc. COMPOSITIONS AND METHODS OF USING CANNABINOIDS TO TREAT STAMMING/STOMMING AND SYMPTOMS OF TOURETTE SYNDROME
WO2021033149A1 (en) * 2019-08-19 2021-02-25 Buzzelet Development And Technologies Ltd. Compositons for the treatment of a condition characterized by anandamide deficiency and uses thereof
EP3838346A1 (en) * 2019-12-20 2021-06-23 Chemo Research SL Soft gelatin capsules comprising palmitoylethanolamide and alpha-lipoic acid
EP4087568A4 (en) 2020-01-10 2024-01-17 Pacira Pharmaceuticals, Inc. Treatment of pain by administration of sustained-release liposomal anesthetic compositions
US20230080593A1 (en) 2020-01-10 2023-03-16 Pacira Pharmaceuticals, Inc. Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions
US11273122B2 (en) 2020-02-11 2022-03-15 Therese Mainella Combination of cannabis, derivatives thereof and additives in oral care compositions
BR112023013685A2 (pt) * 2021-01-11 2023-11-14 Pacira Pharmaceuticals Inc Tratamento da dor no quadril com composições anestésicas lipossômicas de liberação sustentada
WO2023278768A1 (en) * 2021-06-30 2023-01-05 Demetrix, Inc. Alleviation of itching sensations using cannabinoid compounds
WO2023039419A2 (en) 2021-09-08 2023-03-16 Plantible Foods Inc. Systems and methods for measuring mat density of aquatic biomass
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療
US12226610B2 (en) 2022-11-03 2025-02-18 Pacira Pharmaceuticals, Inc. Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
WO2024124354A1 (en) * 2022-12-16 2024-06-20 Aima Inc. Compositions and methods for treating or preventing pain or other disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173550A1 (en) * 1998-05-29 2002-11-21 Antonio Calignano Control of pain with endogenous cannabinoids

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
GB2394894B (en) * 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
WO2007006319A2 (en) 2005-07-14 2007-01-18 Rheoscience A/S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
KR101662871B1 (ko) * 2009-09-07 2016-10-05 에피테크 그룹 에스.알.엘. 초미세화 팔미토일-에탄올아미드를 함유한 조성물
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
EP2719375A1 (en) * 2012-10-10 2014-04-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms
EP4193993A3 (en) * 2015-04-29 2023-07-19 Scisparc Ltd. Combinations of cannabinoids and n-acylethanolamines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173550A1 (en) * 1998-05-29 2002-11-21 Antonio Calignano Control of pain with endogenous cannabinoids

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"THC AND OPIATES: Entourage Effect'' of Prismic's IP-Protected Palmitoylethanolamide Drives New Prescription Drug Strategy", Prismic Pharmaceuticals, Inc, (2015-02-15), page 1 *
COPPOLA M et al., "Palmitoylethanolamide: from endogenous 0cannabimimetic substance to innovative medicine for the treatment of cannabis dependence", (2013-07-26), vol. 81, no. 4, pages 619 - 22 *
MULLER-VAHL KR et al., "Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance", Neuropsychopharmacology, (2003-02-01), vol. 28, no. 2, pages 384 - 388 *
RAHIMI A ET AL, "Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice", NEUROSCIENCE, vol. 290, 279 - 287 *

Also Published As

Publication number Publication date
EP4193993A3 (en) 2023-07-19
US20220071948A1 (en) 2022-03-10
IL255238B (en) 2022-05-01
US20210393577A1 (en) 2021-12-23
AU2021206784A1 (en) 2021-08-12
AU2021206784B2 (en) 2023-07-20
EP3288553A1 (en) 2018-03-07
JP2018514589A (ja) 2018-06-07
AU2016254685A1 (en) 2017-11-09
CA2984088C (en) 2024-04-09
WO2016174661A1 (en) 2016-11-03
MA41997A (fr) 2021-03-31
US20200030281A1 (en) 2020-01-30
US20180078523A1 (en) 2018-03-22
EP3288553A4 (en) 2018-12-26
EP3288553B1 (en) 2022-12-28
DK3288553T3 (da) 2023-01-23
CN116549437A (zh) 2023-08-08
PL3288553T3 (pl) 2023-03-20
ES2935605T3 (es) 2023-03-08
US20200038367A1 (en) 2020-02-06
JP2021107401A (ja) 2021-07-29
AU2023251426A1 (en) 2023-11-09
JP6938465B2 (ja) 2021-09-22
US11197845B2 (en) 2021-12-14
US11234956B2 (en) 2022-02-01
EP4193993A2 (en) 2023-06-14
US20220071949A1 (en) 2022-03-10
AU2023251426B2 (en) 2025-11-27
IL255238A0 (en) 2017-12-31
US11207290B2 (en) 2021-12-28
CN107530317A (zh) 2018-01-02
CA2984088A1 (en) 2016-11-03
US20200022946A1 (en) 2020-01-23
IL291864A (en) 2022-06-01
AU2025287414A1 (en) 2026-01-22

Similar Documents

Publication Publication Date Title
AU2023251426B2 (en) Combinations of cannabinoids and N-acylethanolamines
US9750746B2 (en) ANAVEX2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection
US11116773B2 (en) Method of treating dementia
US12138269B2 (en) Method of treating dementia
CN113924098A (zh) 治疗精神障碍、行为障碍、认知障碍的方法
WO2019130215A1 (en) Cannabis compositions for the treatment of inflammatory skin disorders
WO2023227881A1 (en) Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
HK40085288A (en) Combinations of cannabinoids and n-acylethanolamines
US20220000833A1 (en) Compositions and methods for treating obstructive sleep apnea
US12539323B2 (en) Anti-psychotic composition and treatment methods
IL230174A (en) Pharmaceutical composition for the treatment of premature ejaculation
CA3053916C (en) Anti-psychotic composition and treatment methods
CN121370926A (zh) 一种治疗和/或预防抑郁症的药物组合物及其制备方法、应用
WO2018029685A1 (en) Compositions and methods for treating a fear memory

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: SCISPARC LTD

Free format text: FORMER NAME(S): THERAPIX BIOSCIENCES LTD.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NEUROTHERA LABS INC.

Free format text: FORMER OWNER(S): SCISPARC LTD